Fig. 3 | Blood Cancer Journal

Fig. 3

From: Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

Fig. 3

: a Provides the distribution of all grades of toxicities considered at least possibly related to the drug administration. b Shows the incidence of hematological toxicity across individual cycles, highlighting lack of any cumulative hematological toxicity. c Shows the distribution of Neurotoxicity data by cycle. The horizontal bars are the median total FACT/GOG score for each cycle

Back to article page